@article{bibcite_8021,
  keywords = {Gram negative bacteria, Gram positive bacteria, cell-free system, fungi, human in vivo production, insect cells, mammalian cells, microalgae},
  author = {Esther Veronika Wenzel and Laila Al-Halabi-Frenzel and Seyhan Demiral and Andr{\'e} Frenzel and Dianne Celine Gnann and Martha Charlotte-Elisabeth Keitel and Nina Lehmler and Tarushyam Mukherjee and Justus Rauls and Thomas Schirrmann and Piotr Grzegorz Sta{\'n}czyk and Stephan Steinke and Jan Terbrack and Sofie Westerhoff and Stefan D{\"u}bel and Maren Schubert and Michael Hust and Federico Bertoglio},
  title = {The landscape of antibody production systems: recombinant expression for research, diagnostics and therapy},
  abstract = {Over the past three decades, the emergence of recombinant antibodies has positioned them as the fastest-growing class of therapeutic proteins and as well as crucial reagents for both diagnostics and specific research applications. The industrial production of most therapeutic antibodies currently relies on mammalian cell lines, primarily Chinese Hamster Ovary (CHO) cells, which remain the gold standard in biopharmaceutical manufacturing due to their exceptionally high production yields, robustness, regulatory acceptance, and consistent product quality. Nevertheless, new approaches using specifically adapted expression systems are emerging. These new host organisms enable the production of antibodies with posttranslational modifications that closely resemble those found in the human system, without the need for animal-derived source materials. For diagnostic and research purposes, a broad range of production systems has been developed. These include Gram-negative and Gram-positive bacteria, yeasts, filamentous fungi, insect cell lines, and transgenic plants. Additionally, smaller single domain antibodies and bispecific fragments that do not require glycosylation can be successfully produced in bacteria for therapeutic applications. Some of these molecules have already been approved by regulatory authorities in the European Union and the United States, and several more are currently in clinical trials. This review therefore focuses on the broad and evolving landscape of recombinant antibody production systems and their applicability across various fields.},
  year = {2026},
  journal = {Frontiers in Bioengineering and Biotechnology},
  volume = {14},
  month = {2026-05-20},
  issn = {2296-4185},
  url = {https://www.frontiersin.org/journals/bioengineering-and-biotechnology/articles/10.3389/fbioe.2026.1765764/full},
  doi = {10.3389/fbioe.2026.1765764},
  language = {English},
}